Steglujan (Ertugliflozin/Sitagliptin Phos) Patent Expiration, LOE Window & CMS Spending

Steglujan (Ertugliflozin/Sitagliptin Phos) by Merck & Co.: FDA Orange Book core substance LOE 2031-12-19, 0 AB generics, $1.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN209805 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-12-19
Last Listed Patent or Exclusivity Date2031-12-19
Orange Book Patents (*PED Extensions)5 patents (1 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.9M
2024 Medicare Part D Spend$978K
2024 Medicaid Spend$958K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.